http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 29 Jul 2024 16:11:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++AEON+Biopharma%2C+Inc.+++++++++++++++++++Filed+by%3A+Grodnensky+Oleg/23518264.html si-local-file:///var/storage/secattach/20240729/23518264.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AEON+Biopharma%2C+Inc.+++++++++++++++++++Filed+by%3A+Grodnensky+Oleg/23518264.html Mon, 29 Jul 2024 16:11:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/SEC+Filings/Form++144++++++++AEON+Biopharma%2C+Inc.+++++++++++++++++++Filed+by%3A+Grodnensky+Oleg/23518264.html si-local-file:///var/storage/secattach/20240729/23518264.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AEON+Biopharma%2C+Inc.+++++++++++++++++++Filed+by%3A+Grodnensky+Oleg/23518264.html Mon, 29 Jul 2024 16:11:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++AEON+Biopharma%2C+Inc.+++++++++++++++++/23494793.html <p><a target="_blank" href="http://archive.fast-edgar.com/20240723/AJBOLQ2C8Z229ZZ222ZG2ZZZ9UQOZ2S2D26G">http://archive.fast-edgar.com/20240723/AJBOLQ2C8Z229ZZ222ZG2ZZZ9UQOZ2S2D26G</a></p> <p> Filed on: July 23, 2024 </p> http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++AEON+Biopharma%2C+Inc.+++++++++++++++++/23494793.html Tue, 23 Jul 2024 16:44:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++AEON+Biopharma%2C+Inc.+++++++++++++++++/23494793.html <p><a target="_blank" href="http://archive.fast-edgar.com/20240723/AJBOLQ2C8Z229ZZ222ZG2ZZZ9UQOZ2S2D26G">http://archive.fast-edgar.com/20240723/AJBOLQ2C8Z229ZZ222ZG2ZZZ9UQOZ2S2D26G</a></p> <p> Filed on: July 23, 2024 </p> http://www.streetinsider.com/SEC+Filings/Form++S-1A++++++AEON+Biopharma%2C+Inc.+++++++++++++++++/23494793.html Tue, 23 Jul 2024 16:44:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jul+09/23444531.html si-local-file:///var/storage/secattach/20240709/23444531.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jul+09/23444531.html Tue, 09 Jul 2024 08:07:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jul+09/23444531.html si-local-file:///var/storage/secattach/20240709/23444531.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Jul+09/23444531.html Tue, 09 Jul 2024 08:07:00 -0400 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html <p align="center"><em>– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 –</em></p> <p align="justify">IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced plans to advance a single pivotal clinical development study in cervical dystonia (“CD”) for its lead candidate, ABP-450 (prabotulinumtoxinA) injection, utilizing the 351(k) regulatory pathway for http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Announces+Strategic+Reprioritization+to+Pursue+a+Biosimilar+Pathway+for+ABP-450/23444426.html Tue, 09 Jul 2024 08:00:00 -0400 A.06822034 A.17150087 A.31066700 AEON AEON-WS O.20026344 O.22422661 O.49223070 O.49829186 PMGMU